The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Fox News senior medical analyst Dr. Marc Siegel weighs in on President Donald Trump's pharmaceutical executive order aiming to cut drug prices for Americans. Feeling snacky? Everyone knows you can ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Larger studies are needed to confirm the findings, which offer the latest evidence that the medicines can do much more than ...